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Legionellosis is an acute respiratory disease which occurs throughout
the United States and other areas of the world. The etiologic agent of
this disease is a gram-negative, fastidious bacterium that belongs to the
genus Legionella. The most common species, pneumophila, has been
divided into 7 serogroups. Strains of serogroups 3 and 6 show common
antigens as indicated by cross-reactivity which has been obtained with
rabbit antisera. The objective of this research is to produce monoclonal
antibody against cell surface antigens of L. pneumophila serogroup 6
(Chicago 2 strain), to determine whether there is antigenic heterogeneity
among strains of I^. pneumophila serogroup 6, and to determine whether
monoclonal antibodies to serogroup 6 might be useful as diagnostic
reagents for detecting legionellosis.
Hybridoma cell lines producing monoclonal antibodies for the deter¬
minants of Ij. pneumophila serogroup 6 were derived from the fusion of
mouse myeloma cells and spleen cells from mice immunized with
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I^. pnetimophila Chicago 2 strain. Test sera of mice immunized with Chicago
2 strain were negative against the Bloomington 2 reference strain of
pneumophila serogroup 3. After fusion, the suspension was plated in 10
plates. Screening of Chicago 2 antibody-producing clones by indirect
fluorescent antibody (IFA) was performed throughout the project. The
clones producing the highest fluorescence in each plate were recloned
twice to insure monoclonality. Ten clones producing monoclonal antibodies
against Chicago 2, the representative strain of L. pneumophila serogroup
6, were isolated. These were tested by IFA against 30 strains of I^.
pneumophila serogroup 6 and 6 strains of I^. pneumophila serogroup 3. All
ten of the monoclonal antibodies gave positive results to 30 strains of
serogroup 6 but not to 6 strains of serogroup 3.
It is concluded that monoclonal antibody is superior to the
conventional antisera because of the specificity demonstrated. The
reaction of monoclonal antibodies with 30 strains of I^. pneumophila
serogroup 6 demonstrated that 3 strains showed antigenic variation. These
results also indicate the potential of monoclonal antibodies as diagnostic
reagents for Identification of I^. pneumophila.
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Legionnaires' disease (LD) is an Infectious disease caused by any
member of the pathogenic organisms that belong to the genus Legionella.
The pneumonic form of LD is an acute severe respiratory Illness (Thacker,
et al., 1978). Pneumonic LD is not readily distinguishable from other
bacterial pneumonias on the basis of clinical symptoms. About 25,000
cases of LD occur in the U. S. per year. Of these cases of known outcome,
between 12-20% of cases result in death (Foy, et al., 1979). More than
500 sporadic cases of LD have been reported to the Centers for Disease
Control (CDC) from at least 43 states and the District of Columbia. Nine
species of organism have been reported: pneiunophila (Brenner, et al.,1979), L. bozemanii (Brenner, et al., 1980) dumoffii (Brenner, et al.,1980), micdadei (Hebert, et. al., 1980b), I^. gormanii (Morris, et
al., 1980), L. longbeachae (McKinney, et al., 1981), jordanis,
(Cherry, et al., 1982) wadsworthii (Edelstein, et al., 1982), and ]L.
oakridgensls (Orrison, et al., 1983).
I^. pneumophila has been divided into 7 serogroups (McKinney, et al.,
1979; Bibb, et al., 1983). Serogroups 1-6 were defined on the basis of
fluorescent antibody staining (McKinney, et al., 1979). The strain,
Chicago 2, is the representative strain of serogroup 6 and appears to be
widely distributed geographically (McKinney, et al., 1979). Chicago 8 is
the representative strain of serogroup 7 (Bibb, et al., 1983). There may
be additional undocumented serologic variants of pneumophila around the
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world which are all potentially highly dangerous to human health
(McKinney, R.M., Personal communication). Epidemiologically, Legionella
organisms have been Isolated from water, from cooling towers, evaporative
condensers in air conditioning systems and from streams and natural water
reservoirs. Outbreaks of this disease usually occur in hospitals and
hotels (Blackmon, et al., 1979). The clinical signs of this disease are
not specific and differential diagnosis is complicated. A sensitive and
specific method for detection of this organism would be of great
advantage in diagnosis and ultimately in elimination of the disease.
Direct fluorescent antibody (DFA) testing has proved to be a
sensitive and specific method for detecting Legionella (Cherry and
McKinney, 1979). However, serogroups 3 and 6 show common antigens as
indicated by cross reactivity when tested in the DFA test using
conjugated rabbit antisera. Isolates from serogroups 1, 2, 4, and 5 do
not react with conjugates prepared against isolates of serogroups 3 and
6. Although cross-reactivities between serogroups 3 and 6 exist,
absorption with a strain of one serogroup can eliminate all
cross-reactivities to that serogroup. This, however, reduces the working
concentration of these conjugates. Frequently, sera from patients with
LD do not contain detectable antibodies against the identified Infecting
strain of the Legionnaires' disease bacterium (LDB), whereas, sera from
some other patients infected with dissimilar pathogens may contain
antibodies that react with LDB, either because of similar antigens or
perhaps because of nonspecific stimulation of the reticuloendothelial
lymphocytic system (Wilkinson, et al., 1979). This is a second
difficulty in diagnosis of LDB by immunological techniques. Tests such
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as radioimmunoassay (RIA)(Kohler, et al., 1981) and enzyme-linked
immunosorbent assays (ELISA) (Tilton, 1979; Sathapatayavongs, et al.,
1982) show much promise as rapid diagnostic tests for soluble antigens of
I^. pneumophila in urine. The success of these tests is highly dependent
on the availability of potent and specific antibodies directed against
the appropriate antigens of the Legionella organisms. For these reasons,
the FA test, ELISA test and RIA assays should be used in conjunction with
monoclonal antibodies which can be obtained with hybrldoma technology.
Antibodies that can be used throughout the world as standardized
diagnostic reagents are highly desirable. This has been made possible by
using hybridomas that secrete monoclonal antibody of desired specificity,
which can be obtained in unlimited amounts. Lymphocytes are not
maintained in cultures for very long but a technique has been developed
(Kohler and Milsteln, 1975, 1976), whereby a single antibody-producing
cell can be propagated indefinitely in culture by hybridization with a
tumor cell. Since all of the cells of one clone are derived from a
single lymphocyte, "monoclonal" antibodies of high purity are produced.
A monoclonal antibody can detect specifically a particular epitope of the
set of antigenic determinants thereby eliminating some of the problems of
cross-reactivity encountered using conventional antisera. Monoclonal
antibody produced by hybridomas derived from the fusion of mouse myeloma
and spleen cells of mice that have been Immunized with previously defined
antigen might react with higher specificity to that antigen than would
conventional antisera.
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The purpose of this research was to use hybridoma techniques to
produce monoclonal antibody against cell surface antigens of ]L.
pneumophila serogroup 6 (Chicago 2 strain), to determine whether there is
antigenic heterogeniety among strains of I^. pneumophila serogroup 6, and
to determine whether monoclonal antibodies to serogroup 6 might be useful




The term "Legionnaires' disease" (LD) is used to refer to the illness
caused by the gram-negative bacteria of the genus Legionella. The out¬
break in Philadelphia in 1976 brought LD worldwide attention and led to
the Isolation of the Legionnaires' disease bacteria (LDB) at the Centers
for Disease Control (CDC). LDB is a gram-negative, fastidious organism.
It does not grow on most bacteriological media or grows very slowly
(McDade, et al., 1977), but it can be cultivated on charcoal yeast extract
(CYE) agar (Feeley, et al., 1978).
Isolation of LDB. Originally LDB was Isolated in guinea pigs and
propagated in embryonated hen eggs (McDade, et al., 1979). LDB can be
confirmed by growth on CYE agar, by failure to grow on trypticase soy
agar or blood agar base media, by cellular fatty acid composition (Moss,
et al., 1974), and by studies of DNA relatedness to the type strains of
the Legionella species.
Morphology of LDB. The morphology of the LDB varies widely under
different growth conditions. The cellular morphology changes
progressively when LDB is grown in broth. Large masses of filaments or
chains of bacilli in the logarithmic phase break into shorter filaments
and ultimately form single and double cigar-shaped cells. With prolonged
incubation or limited substrate, cells become coccal shape. No spores or




Nomenclature and Taxonomy of LDB. LDB was named Legionella
pneumophila sp. nov., the type species of genus Legionella (Brenner, et
9
al», 1979). The genome size of LDB DNA was estimated at 2.5 x 10
daltons by reassoclatlon kinetics; a GC content of 39% for LDB DNA was
established by optical thermal denaturatlon and buoyant density
ultracentrifugation measurements (Brenner, et al., 1978). New organisms,
WIGA, Ml-15, LS-13, NY-23, Tex-KL, TATLOCK, HEBA and Pittsburgh pneumonia
agent, were Isolated and resemble pneumophila phenotyplcally (Cordes,
et al., 1979; Thomason, et al., 1979; Hebert, et al., 1980a and Hebert,
et al., 1980b). Brenner, et al. (1980), have proposed these organisms be
Initially described as Leglonella-llke organisms (LLOs) until they are
assigned a permanent name. bozemanll has been proposed for WIGA and
Ml-15 (Brenner, et al, 1980), dumoffll for NY-23 and Tex-KL (Brenner,
et al., 1980), and mlcdadel for TATLOCK, HEBA, and Pittsburgh
pneumonia agent (Hebert, et al., 1980c).
The LDB Is clearly prokaryotic (Murray, 1974) In that It lacks
eukaryotic features such as mitochondria, nuclear membranes, endoplasmic
reticulum, and mitotic division. Prominent features Include electron-
lucent, filamentous nucleoldes Interspread among areas of well-defined
ribosomes; enclosure by a double envelope, each portion of which consists
of a triple layered "unit membrane" (Glavert, 1962) and division by a
pinching, non-septate process. This pinching type of division and double
envelope enclosure are characteristics of gram-negative bacteria
(Glavert, 1962; Steed and Murray, 1966). Electron microscopy shows that
LDB Is a blunt or tapering rod. Because the ultrastructure of the LDB Is
not unique. It may be Impossible to differentiate this organism from
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other small gram-negative bacilli by fine structure alone. The width is
approximately 0.5-0.7 ijm. The length varies from 2-20 pm or more and the
organisms contain flagella as well as flagellum-like appendages. The
cells appear red when counterstained with carbol fuchsin and light pink
when counterstained with safranin.
Epidemiology. Investigations of several outbreaks indicated that the
etiological agent was transmitted in air. Among the environmental sources
implicated were water from air conditioning cooling towers or evaporative
condensers (Click, et al., 1978) and soils disrupted by construction work
and presumably transported as dust by air currents (Thacker, et al.,
1978).
In 1965, an outbreak of an epidemic similar to LD occurred a St.
Elizabeth's Hospital where 81 patients became ill, and 14 died. In 1968,
144 employees and visitors who entered a health department building in
Pontiac, Michigan became ill. In 1973, an estimated eight Scottish
vacationers contracted a disease similar to LD while vacationing in Spain;
three died. In 1974, people who attended a convention at Philadelphia
developed pneumonia and two died. Retrospectively, serologic evidence
was used to show that all of these outbreaks were epidemics of LD. In
1976, the American Legion Convention was held in the Philadelphia's
Bellevue Stratford Hotel; 182 became ill and 29 died. The outbreak in
Philadelphia in 1976 brought LD worldwide attention and led to the
isolation of the LDB at the CDC (McDade, et al., 1977).
Clinical Features. The most common clinical sign in LD is
pneumonia. The onset is usually 2 to 10 days after exposure to LDB, with
malaise, myalgia and mild headache. A non-productive cough is common.
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but sputum production is sometimes associated with the disease. Within
less than a day, the patient may experience rapidly rising fever and
onset of chills. Fever to 39-41 C (102-105 F), and relative
bradycardia. There is no physical finding specific to this disease.
Associated manifestations may Include confusion, chest pain, abdominal
pain, impaired renal function, and diarrhea.
Direct Fluorescence Assay (DFA). Autopsy and biopsy tissue can be
screened for LDB more quickly by the DFA test than by pathological
examination. In addition, the DFA test has a dimension of serological
specificity not possessed by the Dieterle silver impregnation stain or
other histological techniques used to demonstrate the organisms in
tissue. DFA staining has proved to be a sensitive and specific method
for detecting LDB in both clinical specimens and environmental samples
(Cherry and McKinney, 1979).
Indirect Fluorescence Assay (IFA). The difficulty in isolation of
Legionella species from patients has caused heavy dependence on
immunological techniques for diagnosis of legionellosis. The IFA test
was first used by McDade, et al., (1977) to provide serological evidence
that an organism which has been isolated from patients with LD was
actually the causative agent of that disease. IFA tests for serum
antibody are continuing to be adapted (Wilkinson, et al., 1979).
Hybridoma Technology
A new era of immunology evolved with a report describing "Continuous
Culture of Fused Cells Secreting Antibody of Predefined Specificity," by
Kohler and Milstein, (1975). This classic report led to the application
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of monoclonal antibodies in many areas of biology and medicine. In 1978,
a Lymphocyte Hybridomas meeting was held in Bethesda, Maryland. Many
investigators reported the fusion of myeloma to immunized spleen cell
from animals and production of monoclonal antibodies reacting with a broad
variety of antigenic determinants. A succession of studies led to this
Important development. The most Important Include the adaptation of a
myeloma line and the use of an hypoxanthlne guanine phosphorlbosyl
transferase negative (HGPRT ) parent myeloma to allow for selection of
somatic hybrid by Littlefield (1964).
Adaptation of Myeloma Line. Plasmacytomas can be Introduced into
culture, cloned, and maintained as continuously growing relatively
homogenous culture lines. The P3K continuous line was established by
Horlbata and Harris (1970). The MPC-11 continuous line was established
by Margulies et al. (1976a) soon after P3K. P3 and MPC-11 were studied
widely both in terms of immunoglobulin synthesis and stability of the
cell line. It was found that these cell lines were unstable and had a
high rate of loss of H chain synthesis and stability of the cell line.
Non-secreting mutants were also found to occur in high frequency.
Use of HGPRT Mutant for Selection of Hybrid. Littlefield (1964)
was the first Investigator who demonstrated how to select somatic cell
hybrids. There are two sublines from mice known as the L-Llnes: one
resistant to 8-azaguanlne, the other to 5-bromodeoxy uridine (BUdR) (30
]ig/ml). These two drug resistant lines are correlated, respectively,
with deficiencies for the enzymes HGPRT and thymidine kinase (TK) which
are required for phosphorylation of base analogs. Mammalian cells have
two pathways of synthesis of nucleotides: the ^ novo pathway, whereby
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nucleotides are synthesized from sugars and amino acids, and the
"scavenger" pathway, which utilizes the preformed nucleotides,
hypoxanthlne, and thymidine. The de novo pathway can be blocked by
amlnopterln. The operation of the scavenger pathway depends on the
simultaneous presence of TK and HGPRT. Therefore, the drug resistant and
HGPRT parent cells are unable to grow In a medium containing
hypoxanthlne, amlnopterln, and thymidine (HAT). On the contrary, the
hybrids which contain the genes of both parents and, therefore, produce
both TK and HGPRT, grow unhampered In HAT.
Production of mutant myeloma cells lacking of HGPRT Is relatively
easy because the enzyme Is coded for by a gene on the x chromosome.
Mammalian cells possess only one active x-chromosome (lysonlsatlon).
Thus, only a single mutation Is needed to result In total loss of the
enzyme. Thloguanlne or 8-azaguanlne have been used to select for
HGPRT mutants of myeloma cells. Either drug will be toxic only to
cells that have an Intact scavenger pathway. HGPRT mutants will thus
resist the effect of the drug and survive using the ^ novo pathway.
When two antibody-producing cells are fused, the products of both
parental lines are expressed. Each Immunoglobulin chain results from the
Integrated expression of one of several V and C genes coding respectively
for Its variable and constant sections (Cotton and Mllsteln, 1973). In
view of the production of heavy chains from myeloma parent lines. It was
desirable to develop a non-secreting myeloma line. Sp2/0-Agl4, was
Isolated as a re-clone of Sp2/HL-Ag, Itself derived In several steps from
Sp2/HLGK, a hybrid between a BALB/c spleen cell contributing a IgG2b(H)
and K(L) chain with anti-sheep blood cell activity and a myeloma cell
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line X63-Ag8 IgG^(H) and K(L) (Kohler and Mllsteln, 1975). Sp2/0-Ag 14
Is resistant to 20 yg/ml of 8-azaguanlne, dies in HAT supplement medium
and synthesizes no Ig chains (Kearney, et al., 1979). It has about 73
chromosomes, which is only eight more than the chromosome number of
X63-Ag8, a cell line commonly used to generate hybrldomas (Schulman, e^
al., 1978).
Fusing Agents. Sendai virus was first used for promoting fusion by
Harris and Watkins (1965). Later on, many investigators attempted to
fuse mouse myeloma with mouse myeloma by using Sendai virus for promoting
fusion. These were for the most part unsuccessful because few mouse
myelomas contain receptors for Sendai virus. Cotton and Milstein (1973)
were successful in fusing mouse and rat myeloma by using Sendai virus.
These hybrids continued to produce mouse heavy and light chains and rat
light chain.
Kohler and Milstein (1975) and Margulies, et al., (1976b) succeeded
in fusing mouse myeloma with mouse myeloma by using Sendai virus as the
fusing agent. True hybrids had been formed. These experiments led to
the new era of immunology in studying of monoclonal antibody. The
resulting hybrids had three major characteristics;
(1) Hybrids can be formed between myeloma parent cells;
(2) The expression of immunoglobulin chains produced by both
parental cells lines occurred; and
(3) The total nvimber of chromosomes in the hybrids is less
than the sum of the parental complements, indicating
chromosome loss.
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The hybridization techniques continued to improve. Davidson and
Gerald (1976) improved techniques for induction of mammalian cell
hybridization by polyethylene glycol (PEG). They reported that the
concentration and time of exposure to PEG were important and that fusion
frequencies could be Increased appreciably under appropriate condition.
Norwood, et al., (1976), reported that the fusion efficiency was high in
the presence of 5% DMSO. Fazekas and Scheldlgger (1980) also reported
that lower molecular weight PEG proved less efficient and some of them
were obviously toxic. Temperature and pH of the medium also Influenced
the fusion efficiency. Thirty and fifty percent PEG concentrations were
recommended by many investigators.
CHAPTER III
MATERIALS AND METHODS
Figure 1 shows a flow chart of the basic method used to fuse immunized
mouse spleen cells with 8-azaguanine-resistant myeloma cells (Sp2/o-Agl4).
Chicago 6, the representative strain of organisms in serogroup 6, was
used as an immunogen. Polyethylene glycol (M.W. 1000) is used as the
fusing agent and hypoxanthine, aminopterin, and thymidine medium is used
for selecting stable, monoclonal antibody producing hybrid cell lines.
Antigen Preparation
Chicago 2 strain of Legionella pneumophila (serogroup 6) was obtained
from Dr. Roger McKinney, Supervisor of the Immunodiagnostic Methods
Laboratory, Biotechnology Branch, Centers for Disease Control, Atlanta,
Gerogia. These organisms were subcultured in Buffered Charcoal Yeast
Extract (BCYE). The Innoculatlon slants were incubated at 37 C for about
48 hours. The organisms were Inoculated into tryptic soy agar and
Incubated at 37 C for about 48 hours in order to check for contamination
by other organisms. The antigen Identity was confirmed by Direct
Fluorescent Antibody (DFA) test. One percent of formalin in phosphate
buffered saline (PBS, Appendix F) was used to harvest and inactivate this
antigen. It was centrifuged at 2,000 rpm for 30 minutes and the pellet
was resuspended in 0.5% formalin PBS (Appendix F). The turbidity of the
cell suspension was compared with McFarland Standard #3 (McFarland
g
Nephelometer Density Standards; approximately 9 x 10 cells/ml). For
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Fig. 1. Flow chart indicating steps in the production of
hybrid cell lines secreting monoclonal antibody.
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injection, a portion of the antigen suspension was mixed with an equal
volvune of Freund's complete adjuvant (Difco Laboratories, Lot #0638-60) in
Mulsi Churn Luer Lock syringe (Mulsi Jet Inc., Elmhurst, III.).
Production of Antisera in Mice
The emulsified immunogen was transferred into a tuberculin plastic
syringe before Injection into mice. The remainder of emulsified Immunogen
was kept for one month in order to check for separation of emulsifying
agent and the antigen. Twelve-to-fifteen-week old female BALB/c mice were
used. Each mouse was injected intraperitoneally with approximately 9 x
10^ cells. Each mouse was marked for identification. A booster, with
g
1.8 X 10 cells of antigen suspended in 0.5% formalin PBS (Appendix F),
was given intravenously 30 days after the first immunization and four days
before undertaking fusion. The titer of antibody was checked before the
booster injection and before fusion in order to determine which mice gave
rise to the highest titer. Once the titer was determined, the three mice
with the highest titer were killed and their spleens removed to obtain
antibody producing B-lymphocytes.
Preparation of Peritoneal Macrophages
BALB/c mice were killed, sterilized with 70% alcohol and the abdominal
skin was removed, leaving the peritoneum intact. The peritoneum was then
sterilized with 70% alcohol. Five ml of Hanks Balanced Salt Solution
(HBSS) without Ca++ or MgH- were Injected into the peritoneal cavity with
a 26 gauge, 3/8 inch needle. After gently massaging the abdomen or
shaking and pulling the mouse's legs, the fluid was withdrawn.
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The peritoneal macrophage cells were collected in a 50 ml centrifuge tube
(Corning). The cells were washed with 40 ml Dulbecco's Modified Eagle
Medium (DMEM) containing antibiotics by centrifugation at 800 rpm for 10
minutes at room temperature. The cell pellet was resuspended in 10 ml of
DMEM with hypoxanthlne-amlnopterln-thymidine (HAT) (Appendix C). The
suspension was counted and adjusted to contain 1.5 x 10^ cells/ml (equal
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to 1.5 X 10 cells/well). Cells were plated by dropping 2 drops with a
10 ml pipette (approximately 0.1 ml) of peritoneal macrophage cells into
each well of 96-well tissue culture clusters with flat bottom wells
(Costar, 96-well plate). Preparation of peritoneal macrophage cells was
done 24 hours before fusion and the plates were checked for contamination
before preparation of spleen cells.
Preparation of Spleen Cells
Animals were killed by cervical dislocation. Seventy percent ethanol
was used to sterilize the animals. Each animal was placed facing up in a
sterile petri dish. The skin was pinched at the stomach area and cut with
scissors. The skin was pulled aside on both sides of the slit and split
horizontally. The peritoneum area was disinfected with 70% alcohol and
then the peritoneum which covered the spleen was removed. The spleens
were removed, minced with sterile scissors, and pressed through the
screen with a sterile spatula. Ten ml cold DMEM with antibiotics without
Fetal Bovine Serum (FBS) (Appendix D) was used to suspend the cells.
The cell suspension was drawn sequentially through 19, 21, 23, and 25
gauge needles in order to separate the spleen cells. The cell suspension
was redrawn with the 25 gauge needle and discharged into a 50 ml
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centrifuge tube (Corning 50 ml/centrlfuge tube with screw cap,
polypropylene 25330). The volume was brought to 50 ml with cold DMEM
containing antibiotics. The cells were pelleted by centrifugation at 800
rpm for 10 minutes. The supernatant was discarded and the cell pellet was
resuspended in 30 ml DMEM and recentrifuged. Again, the cell pellet was
resuspended in 5 ml of DMEM. Cells were counted and adjusted to 2 x 10^
cells/ml in 5 ml of solution. The prepared cells were incubated in a 37 C
water bath until fusion was accomplished.
Preparation of Myeloma Cells
Mouse myeloma cells (Sp2/0-Agl4) for use in hybridoma production were
obtained from Mr. David E. Wells, of the Centers for Disease Control,
Atlanta, Georgia. Three vials of myeloma cells were thawed out of liquid
nitrogen and dipped quickly in a 37 C water bath. As soon as liquified,
the cells were taken out with a sterile pasteur pipette and they were
transferred into a 50 ml centrifuge tube containing cold growth medium.
The cells were pelleted and washed again with cold medium. Cell
2
monolayers were grown in Tissue Culture Flasks with 25 cm growth area
(Falcon, lot no. 00882477). Cells were incubated in 10% CO2 with 95%
relative humidity (Appendix G). Cells were grown to about 75-100%
2 2
confluency and transferred from 25 cm growth area (T-25) to 75 cm
growth area (T-75) (Flask cat. #25115) and to 150 cm^ (T-150) (corning.
Tissue Culture Flask, polystyrene), respectively. When the cells in T-150
were 75-100% confluent, they were split to T-150 and fed with fresh growth
medium. Four flasks of T-150, 75-100% confluent, were needed (enough for
one fusion). DMEM with supplement containing 20% fetal calf serum (FCS)
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(Hyclone Bovine Serum Lot #100355) was used to grow myeloma cells. The
myeloma cell cultures were started 10 days before fusion. The day before
fusion, the culture was fed with new medium to Insure healthy cells.
Growth of cells was evident when the media changed from pink to yellow,
indicating acid production, or cells were checked microscopically for cell
growth. To obtain myeloma cells for fusion, the flasks were shaken
vigorously to dislodge cells from the bottom. The cells were collected by
centrifugation at 800 rpm for 10 minutes. The supernatants were removed
and sterilized by filtration for use as conditioned medium. The cell
pellet was resuspended and washed in 50 ml DMEM with antibiotics by
centrifugation at 800 rpm for 10 minutes. The cell pellet was resuspended
with DMEM and the suspension was adjusted to contain 2 x 10^ cells/ml.
Cell viability was 97%. Cells were incubated in a 37 C water bath until
fusion took place.
Hybridization
After the spleen cells and myeloma cells were prepared, fusion was
accomplished as follows:
Polyetheylene glycol 1000 (8U218, J.T. Baker, TM grade. Lot #049385)
was warmed to 37 C before use; DMEM was kept cold. The myeloma cells and
g
spleen cells (1 x 10 cells each) were mixed in a 50 ml conical
centrifuge tube (Coming, 50 ml/centrifuge tube with a screw cap,
polypropylene 25330) and pelleted by centrifugation at 800 rpm for 10
minutes at room temperature. The supernatant was carefully aspirated from
cells. The pellet was left as dry as possible. The tube was flicked to
loosen the pellet and placed in a 37 C water bath. Fusing agent (0.2 ml
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of 30% PEG 1000 in DMEM with 0.15 M HEPES) was added to the pellet and
suspended by swirling. The suspended cells were centrifuged immediately
at 800 rpm for 3 minutes at room temperature. The cell pellet was left
exposed to PEG for 8 minutes. Five ml of DMEM with 0.15 M HEPES was added
slowly with little suspension of the cell pellet. After 1-2 minutes, the
cell pellet was suspended by intermittent swirling for 3-4 minutes,
centrifuged at 800 rpm for 5 minutes, and the supernatant was aspirated.
The cloning medium (Appendix D) (25 ml) was added to the fusion pellet.
The cell pellet was left undisturbed for 6 minutes and then, gently
suspended by swirling or with a pipette one time (no attempt was made to
break all the cell clumps). Unfused spleen cells (2.5 x 10^ cells) were
added to the suspension and the volume was brought to 50 ml with cloning
medium (Appendix D). The suspension was plated at 0.05 ml/well (1 drop
with a 10 ml pipette) into ten 96-well tissue culture clusters seeded with
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1.5 X 10 peritoneal macrophage cells/well. The plated cells were
Incubated undisturbed in a 10% carbon dioxide Incubator for 4 days. At
day 5 and day 12, 2 drops of medium were added to each well of the cloning
plate with a 10 ml pipette. The clones appeared at approximately day 10.
The well containing a clone was marked by looking in a mirror (Microtiter,
Cook Engineering Company). Before collecting supernatant for testing, the
cloning plates were checked in detail with a microscope for tiny clones
which may have appeared late and could not be seen in the mirror.
Initial Screening for Positive Hybrids
Between 14-21 days after cell fusion, the supernatant media of
cultures were harvested using a separate pipette for each well. Pipettes
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were flamed before using. The supernatant solutions were tested undiluted
for the presence of antibody of Interest using the Indirect
Immunofluorescence Antibody Test (IFA) as follows:
Indirect Immunofluorescence Antibody Test (IFA)
Preparation of Antigen. A 25 x 75 mm acetone resistant glass slide
with 30 staggered wells 2 mm In diameter (Cell-Line Associates, Inc.,
Menlsota, N.J.) was used for the IFA test. Formalin-treated cells for
Immunization were washed two times In 0.5% formalin In PBS as In the
preparation of antigen above. Two mlcrollters of diluted antigen
suspension was dropped over the ringed areas of a FA slide. The smears
were air dried and gently heat fixed.
Preparation of Antibody. A 1:10 dilution of serum of Immunized mice
was prepared In 0.2 M phosphate buffered saline, pH 7.6 (Appendix F).
Doubling dilutions were made through 1:2048 In plain PBS. Rigid
polystyrene U-bottomed mlcrotltratlon plates (Llnbro Scientific Co.) and
an automatic dlluter (Cooke Engineering Co.) were used. With a capillary
tube, a drop of each serum dilution, or supernatants from tissue culture,
was smeared In each well of the fixed antigen on the slide. The slide was
Incubated In a moist chamber (petrl dish containing moist filter paper) at
37 C for 30 minutes. The slide was rinsed quickly with PBS and placed In
a PBS bath for 15 minutes. It was removed from the bath, rinsed with
distilled water for 7 minutes and gently blotted dry. A drop from a
capillary pipette (approximately 20 mlcrollters) of fluorescein
Isothiocyanate (FITC)-labeled goat antimouse Immunoglobulin was placed In
each well. The slide was Incubated as above for 30 minutes. The slide
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was rinsed quickly with PBS, placed in a PBS bath for 15 minutes, rinsed
quickly with water, and gently blot dried. The antigen-antibody complex
on the slide was fixed one minute with Kirkpatrick's fixative agent
(Appendix F) and dried. Three drops of buffered glycerol (Appendix F)
were added onto each FA slide and the slide was covered with a 24 x 60 mm
cover glass (Corning). Slides were observed under oil immersion with a
Leltz Dialux 20 fluorescence microscope equipped with an HBO-100 mercury
incident light source and the Leitz I-cube filter system (2 x KP490 and a
1 mm GG 455 primary filter, TK 510 dichroic beam-splitting mirror and
secondary filter).
Fluorescence intensities were read as follows:
4+ = Maximum fluorescence, brilliant yellow-green staining of bacteria
cells.
3+ = Less bright yellow, green staining.
2+ = Less brilliant but definitive fluorescence.
1+ = Barely visible staining
+ = Questionable staining.
0 = No staining.
Tissue culture fluid was used undiluted in the IFA test for monoclonal
antibody. Fluorescence above 1+ intensity indicated a positive clone for
screening of positive hybrids. The serum titration end point was the
highest dilution of serum that gave 1+ fluorescence intensity. The titer
is the reciprocal of the dilution factor.
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Direct Fluorescent Antibody Procedure (DFA)
This procedure was used to confirm antigen before Immunization Into
mice and classification of 36 antigens for characterization of monoclonal
antibody. The antigen for the DFA test was prepared as described In the
IFA test. Twenty mlcrollters of diluted antigen suspension was dropped
over the ringed areas of a FA slide (Fluoro-Sllde, A.S. Aloe Co.); smears
were air dried and gently heat-fixed. Antigen smears were stained by the
direct FA procedure. One drop of conjugate was spread evenly over the
antigen, and the slides were kept In a moist chamber at room temperature
for 30 minutes. They were rinsed with PBS and put In PBS for 15 minutes.
They were then rinsed one minute In distilled water and air dried. Three
drops of mounting fluid (Appendix F) were placed on the smear and a 24 x
60 mm cover slip applied. The slide was read as described above.
Cloning by Limiting Dilution
The most Important principle for the recovery of stable active clones
was to clone early and redone frequently. Between 10-15 days after
fusion, macroscoplcally visible colonies of hybrid cells appeared. Before
cloning, the diameter of clones was approximately 2 mm. The clones were
kept healthy by feeding with one-half volume of new medium the day before
cloning. Only single clones with the highest fluorescent Intensity (2+ -
A
4+) were selected. Feeder cells (peritoneal macrophages 1-4 x 10
cells/well were prepared on the day before fusion and checked for
contamination before cloning. The selected clone was picked up In a
sterilized pasteur pipette, dispersed, counted and serially diluted until
the suspension contained an average of 5 cells/ml. One-tenth ml of this
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dilution was added to each well to give an average of 0.5 cell/well.
Secondary and Tertiary Screening for Positive Hybrids
The methods and procedure were the same as for initial screening. The
exception to this is that after the cells in 24-well plates had grown
approximately to 75-100% confluency, the fluid was collected for the IFA
test and the cells were transferred to T-25 flasks in DMEM medium with
HAT. After the cells reached approximately 75-100% confluency in the T-25
flask, the fluid was tested again and the cells were transferred to a T-75
flask. The old flask was fed and continued to grow and the cells were
frozen. The cells in the T-75 flask were fed with DMEM with hypoxanthlne
and thymidine, but without amlnopterin. Tissue culture cells were grown
to 75-100% confluency in the T-75 flask. The culture fluid was collected
for monoclonal antibody characterization and the hybridoma cells were
frozen as described below.
Freezing of Hybridoma Cells
To preserve hybridomas which produced an antibody of interest, cells
were frozen at -80 C. The freezing medium contained 8% of dimethyl-
sulfoxide (DMSO, Merk, West Germany). The hybridoma cultures were col¬
lected and centrifuged at 1000 rpm for 10 minutes. The cells were
resuspended in cold freezing medium at approximately 10^ cells/ml and
placed into sterile 2 ml screw-cap vials. Vials were closed air-tight and
placed in a styrofoam bag which had about 1 cm thick walls. Vials were
put in -70 C for one day and transferred to a freezing box at a
temperature below -80 C.
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Freezing of Cloning Plates
After Initial, secondary and tertiary screening for antibody and
cloning by limiting dilution, the plates were fed one day before freezing
by removal of one-half of the old medium from each well and adding two
drops of fresh medium to each well. On the day of freezing, the medium
was aspirated from each well and 0.05 ml of freezing medium was added.
The plates were frozen as rapidly as possible at -80 C.
Characterization of Monoclonal Antibody
The monoclonal antibodies were characterized by their reactions
against thlrty-slx antigens which were prepared In the following manner.
Buffered charcoal yeast extract slants were Innoculated with the
appropriate I^. pneumophila strains and Incubated for 16 hours at 37 C.
Cells were harvested In 1.0% formalin PBS solution. The suspensions were
then Incubated for 16-24 hours at 4 C to kill the cells. Killed cells
were washed two times and resuspended In 0.5% formalin PBS to a
concentration which yielded approximately 200 organisms per microscopic
field smear under the 100 X objective. Strains of L. pneumophila were
representative of serogroups 3 and 6 (Appendix B). Each antigen
suspension was checked by DFA using absorbed conjugates to Insure that the
strains were assigned to the correct serogroup. Monoclonal antibodies




Failure of the antigen to grow on tryptic soy agar Indicated that the
pneumophila strain used for Immunization was not contaminated by other
organisms. Antigens used In IFA and DFA tests were tested with serogroup
6 and serogroup 3 - specific conjugates to ensure the organisms were
categorized In the proper serogroup (Tables 1 and 2). Flagella were not
observed In DFA or IFA tests. All antigen preparations were stained as
expected. Cells of Chicago 2 varied In size.
Production of Antisera In Mice
Sera obtained from Immunized mice via the supra orbital plexus were
tested by IFA to determine the extent of the Immune response. The titers
of the antisera were not high (Table 3). Excluding mice 4, 6, 7, and 9,
antibody titers did not Increase following the 2nd Immunization.
Antibody titers of mice 2 and 3 decreased, and the antibody titer of
mouse 1 did not change. A four fold Increase In titer was observed In
mouse 4. Even though the mice apparently did not respond well to the 2nd
Immunization, spleens of mice 1, 3, and 4 were selected as a source of
lymphoid cells for use In fusion experiments IALDCH2 and IBLDCH2.
For fusion experiment 2LDCH2, spleens of three mice (#5, 6 and 9)
(Table 3) were selected as the source of Immune cells. Generally, these
mice responded better than the mice used In the other fusions. The end
point titers were higher and the anamnestic response more pronounced.
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UCH 5 0 3+
SF 7 0 3+
80-011839 0 3+
Chicago 3 0 4+
Toronto 794 0 3+
Indy 4 0 3+
UCH 14 0 3+
GU 11560 lA 0 3+
SF 5 0 3+
UCH 10 0 4+
Adelaide 3 0 4+
Oxford 2 10-17 0 4+
UCH 2 0 4+
Denver 2 0 4+
UCH 11 0 4+












Cleveland 2 0 4+
Houston 2 0 4+
UCH 8 0 4+
Concord 2 0 CM
UCH 13 0 4+
UCH 4 0 4+
SF 4 0 3+
Pittsburgh 8 0 3+
UCH 6 0 4+
Greenfield 1 0 3+
Oxford 1 0 4+
UCH 3 0 4+
Chicago 4 0 2+^^
Albany 1 0 2+^
^ These antigens were tested against serogroup
specific conjugate by DFA at least 4 times.
^ Concord 2 strain shows less fluorescent intensity,
c Chicago 4 strain shows less fluorescent Intensity.
Albany 1 strain shows less fluorescent Intensity.
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UCH 9 4+ 0
Detroit 5 4+ 0
SRP 8 4+ 0
Burlington 4 3+ 0
UCH 1 4+ 0
UCH 12 4+ 0
® These antigens were tested against serogroup specific
conjugate by DFA at least 4 times.








1:80 1:160 1:320 1:140 1:1280 1:2560
IFA values against
Bloomington 2 strain
1* S.D.® 3+ 3+ 3+ 2+ 1+ + 0 0 0 0
D.D.'’ 3+ 3+ 2+ 1+ 1+ + 0 0 0 0
2 S.D. 4+ 4+ 3+ 2+ 2+ 1 + 0 0 0
D.D. 3+ 3+ 3+ 2+ 1+ 0 0 0 0 0
3* S.D. 4+ 4+ 3+ 2+ 1+ + 0 0 0 0
D.D. 4+ 4+ 3+ 1+ 0 0 0 0 0 0
4* S.D. 2+ + 0 0 0 0 0 0 0 0
D.D. 2+ 2+ 1+ 0 0 0 0 0 0 0
5* S.D. nt'^ NT NT NT NT NT NT NT NT 0
D.D. 3+ 3+ 3+ 3+ 3+ 3+ 0 0 0 0
6* S.D. 3+ 2+ 1+ + 0 0 0 0 0 0









1:80 1:160 1:320 1:140 1:1280 1:2560
IFA values against
Bloomington 2 strain
7 S.D. 3+ 3+ 3+ 3+ 3+ 2+ 1+ + 0 0
D.D. 3+ 3+ 3+ 3+ 3+ 2+ 2+ 1+ 0 0
8 S.D. 3+ 3+ 3+ 2+ 2+ 1+ 0 0 0 0
D.D. 3+ 3+ 2+ 2+ 2+ 0 0 0 0 0
9* S.D. 2+ 2+ 2+ 2+ 2+ + 0 0 0 0
D.D. 3+ 3+ 3+ 3+ 3+ 2+ 2+ 1+ 0 0
®S.D. is the single dose (Immunization I/P with complete Freunds).
^D.D. Is the double dose (Boost I/V)
^NT Is not tested due to the failure to collect blood
*These mice were selected to obtain spleen cells.
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The secondary responses in mice 6 and 9 were 4 and 8 times the primary
response, respectively.
Initial screening for positive hybrids. Results of the initial
screening for positive clones by IFA are shown in Figure 2. The total
number of clones appearing was 145. Five of them did not produce antibody
against either Chicago 2 or Bloomington 2. Sixty-four clones gave 1+, 59
clones gave 2+, 15 clones gave 3+, and 6 clones gave 4+ fluorescent
intensity against Chicago 2 antigen. All the of supernatants tested were
negative to Bloomington 2 antigen (data not shown).
Twenty-five clones were selected on the basis of their positive
IFA reaction and recloned by limiting dilution (Table 4). The first
clones appeared approximately ten days after plating and they grew for
three weeks before testing for antibody production. Only nine of the
original positive hybridomas continued to produce antibody after the
cloning process (Table 4).
Secondary screening for positive hybrids. Results of IFA testing
are shown in Figure 3. The total number of clones appearing were 550.
Fifty percent of clones did not produce antibody. Ten of the positive
clones were recloned a second time.
Tertiary screening for positive hybrids. Fifty to eighty percent
of the fluids from cells with clones gave 4+ fluorescent intensity (Figure
4). The total number of clones which appeared in each plate varied from
plate to plate (Table 5). Most of the clones appeared within 2 weeks of
incubation. Almost 100% of the clones from the tertiary screening
produced monoclonal antibodies against Chicago 2 strains.
Fig. 2. Reactivity of clones against Chicago 2
obtained from Initial screening of fusions
IALDCH2, IBLDCH2, and 2LDCH2
0 = negative
1+ = very weak positive
2+ = weak positive















lALDCH® 1A12 0.5 6 0
1B12 1.0 4 0
1D9 0.98 22 0
1G7 1.0 12 0
2H4 0.9 8 0
2H11 0.1 30 0
3B2* 1.0 29 29
3E11* 1.0 31 28
4B1 1.03 26 0
5A5 1.0 14 0
IBLDCH2 3A11 0.5 28 0
3C3 0.5 0 0
3C6* 1.0 26 20
4F1 0.42 0 0


















5A1 1.0 22 0
5C1 1.0 4 0
2LDCH2 1H7 0.5 39 39
IHll* 0.5 60 60
2H5 0.5 13 13
4D1* 1.0 65 65
4E4 0.5 6 6
5C1* 1.0 30 27
® IALDCH2 is the experiment number 1 part A,
fusing agent containing 0.15M HEPES.
^ IBLDCH2 Is the experiment number 1 part B,
fusing agent containing no HEPES.
c 2LDCH2 Is the experiment number 2,
fusing agent containing 0.15M HEPES.




Fig. 4. Reactivity of clones against Chicago 2
obtained from tertiary screening of fusions
IALDCH2, IBLDCH2, and 2LDCH2
0 = negative
1+ = very weak positive
2+ = weak positive















1ALDCH„ 3B2-2B10 0.5 54 54
3E11-2E7 0.5 48 48
IBLDCH^ 3C6-1D7 0.5 24 22
3C6-1H9 0.5 59 59
2LDCH^ 1H11-1C2 0.5 50 50
1H11-1B3 0.5 45 45
4D1-1C10 0.5 36 36
4D1-1F2 0.5 55 55
4D1-1F3 0.5 56 56
5C1-1B8 0.5 4 4
38
The ten monoclonal hybridomas were then expanded after tertiary
screening. The fluids were collected after 3 days of culture on
confluent monolayers. The monoclonal antibodies were then tested against
30 strains of pneumophila serogroup 6, and 6 strains of
pneumophila serogroup 3.
Characterization of Monoclonal Antibodies
Table 6 summarizes the data obtained from analysis of reactivity
patterns of ten monoclonal antibodies. Seven antigens. Indy 4, UCH 10,
UCH 2, UCH 4, UCH 8, UCH 13, and UCH 11 reacted very well with all of ten
monoclonal antibodies. UCH 14, Cleveland 2, UCH 3, Oxford 1, and Houston
2 reacted strongly with monoclonal antibodies numbers 6-10. Concord 2,
Chicago 4 and Albany 1 gave negative results to most of 10 monoclonal
antibodies. All six strains of pneumophila serogroup 3 gave negative
results to all monoclonal antibodies
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Table 6. Indirect Fluorescent Antibody Reactivity Patterns of Ten
Monoclonal Antibodies with 30 strains of L. pneumophila serogroup 6
Monoclonal Antibody
Representative Strain 1 2 3 4 5 6 7 8 9 12.
Serogroup 6
1. UCH 5 3^ 3 3 3 3 3 3 3 3 3
2. SF 7 3 3 3 3 3 3 3 3 3 3
3. 80-011839 3 3 3 3 3 3 3 3 3 3
4. Toronto 794 3 3 3 3 3 2d 3 3 3 3
5. Indy 4 4b 4 4 4 4 4 4 4 4 4
6. UCH 14 3 3 3 3 3 4 4 4 4 4
7. GU 115601 3 3 3 3 3 3 3 3 2 3
8. SF 5 3 3 3 3 3 3 3 3 3 3
9. UCH 10 4 4 4 4 4 4 4 4 4 4
10. Oxford 2 3 3 3 3 3 3 3 3 3 3
11. Adelaide 3 3 3 3 3 3 3 3 3 3 3
12. UCH 2 4 4 4 4 4 4 4 4 4 4
13. Denver 2 3 3 3 3 3 3 3 3 3 3
14. UCH 7 3 3 3 3 3 3 3 4 3 3
15. Cleveland 2 3 3 3 3 3 3 3 4 4 4
16. Concord 2 4 _e - - - 3 - 3 - -




Representative Strain 1 2 3 4 5 6 7 8 9 12.
Serogroup 6
18. SF 4 3 3 3 3 3 3 3 3 3 4
19. Pittsburgh 8 3 2 3 3 3 3 3 3 3 3
20. UCH 6 3 3 3 3 3 3 3 3 3 3
21. Greenfield 1 4 3 3 3 3 3 3 3 3 3
22. Oxford 1 3 3 3 3 3 4 3 3 4 3
23. UCH 3 3 3 4 4 4 4 4 4 4 4
24. Chicago 4 3 2 - - - - - 2 - -
25. UCH 8 4 4 4 4 4 4 4 4 4 4
26. UCH 13 4 4 4 4 4 4 4 4 4 4
27. Houston 2 3 3 3 3 3 4 4 4 4 3
28. UCH 11 4 4 4 4 4 4 4 4 4 4
29. Chicago 3 3 3 3 3 3 3 3 3 3 3
30. Albany 1 - - - - - - - 2 2 -
® Number designation given to the monoclonal











The procedure proposed In this investigation offers an alternative to
conventional serological techniques used for infectious disease in most
laboratories. Monoclonal antibodies for detection of infectious disease
is a relatively new immunologic technique. This research objective was
to use hybridoma techniques derived by various Investigators to allow
production of monoclonal antibodies against cell surface antigens of
pneumophila serogroup 6 (Chicago 2 strain), to determine whether there
is antigenic heterogeneity among strains of I., pneumophila serogroup 6
(Chicago 2 strain), and to determine whether monoclonal antibodies to
serogroup 6 might be useful as diagnostic reagents for detecting
legionellosis. pneumophila serogroups 3 and 6 appear to be widely
distributed geographically. These two serogroups share common antigens
as indicated by strong cross reactivities when tested in the DFA test
using conjugate against the heterogenous strain. The results (Table 6)
show that ten monoclonal antibodies produced by hybridomas derived from
the fusion of mouse myeloma cells and spleen cells of mice that have been
immunized with Chicago 2 strain (serogroup 6) will react only with the
antigens in serogroup 6. None of these ten monoclonal antibodies reacted
with antigens in serogroup 3 (data not shown). Seven strains of
pneumophila serogroup 6 reacted very well with all ten monoclonal
antibodies. Two additional strains gave relatively high fluorescent
intensity with monoclonal antibodies number 6-10.
41
42
Three strains (Concord 2, Chicago 4, and Albany 1) did not react with
monoclonal antibodies designated, 3,4,5,6,7,9 and 10. Concord 2,
Chicago 4, and Albany 1 produced weak reactions with absorbed polyclonal
antibodies (Table 1).
With current technology, many investigators suggest that they would
not attempt a fusion unless they have animals whose serum titers had
risen about 100 fold, three days after boost. Results of these
experiments Indicate that monoclonal antibodies can be obtained with mice
having lower titers and lower secondary responses. The group of mice
(mice #1, 3 and 4) used for the first fusion (fusion # IALDCH2 and
IBLDCH2) had serum titers of 160, 80 and 40, respectively, and very
little secondary response. Mice used for the second fusion (2LDCH2)
had serum titer Increases of up to 8 fold, three days after boost.
Results from Table 4 show that only 2 clones (3B2 and 3E11) from
IALDCH2 and only one clone (3C6) from IBLDCH2 continued to produce
antibody, the remaining 16 clones failed to produce antibody. From the
second fusion, 2LDCH2, every clone continued to produce antibody. Loss
of secretors may be due to overgrowth by non-secretors or to loss of
chromosomes. In cases where detectable levels of serum antibody are low
it could be explained that in the second dose of Immunogen all of the
antigens have not cleared. Therefore, antigen-antibody complex may be in
a form such that antibody cannot be detected. The titer may already be
at a maximum.
It is of interest that in this experiment we did not detect any clone
producing antibody that was reactive with I^. pneumophila serogroup 3
strains, although cross reactivities between Chicago 2 and Bloomington 2
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antigens have been observed with rabbit antibodies (McKinney, et al.,
1979). From experimental results In Table 3 serum antibody from mice
Immunized with Chicago 2 did not react with Bloomington 2 antigen. It
appears that the mice In this study did not produce antibody against the
common antigenic determinants which are shared between these two
serogroups.
It Is possible that radioimmunoassay (RIA) may be superior to the FA
method for screening hybrldoma fluids although both methods are analogous
In concept and sensitivity. Only hybrldomas producing antibodies to cell
surface antigens can be detected by the IFA method. If a RIA had been
used to screen for antibody producing hybrldomas, antibodies to both
surface and Internal antigens of ]L. pneumophila (Chicago 2) could have
been detected. Furthermore, the evaluation of FA slides Is laborious and
time consuming and also depends on the judgment of the Individual for
accurate Interpretation. When the eye of the Inspector Is fatigued,
positive clones may be judged as negative and result In failure to detect
clones that produce antibody which has cross reactivity with Bloomington
2 antigen.
Antigens used for detection of antibody In supernatants played an
Important role In detection of monoclonal antibody. After harvesting an
antigen from the culture medium, this antigen must be washed to produce
an antigen which will not bind non-speclfIcally to the conjugate.
The amounts of antigens on the FA slide were found to be Important.
It Is shown that there are limiting quantities of antigen which are
appropriate on the FA slide and give optimum fluorescent Intensity with
antibody. Excess antigen on the FA slide can reduce the apparent
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fluorescent intensity. It is my observation that approximately 200
cells per microscopic field (1,250X) gave the best result for
characterizing monoclonal antibodies. When the optimum concentration of
antigen is obtained, the specific antibody reaction is demonstrably
greater.
The results (Fig. 2) provide evidence that production of antibody
specific for the immunogen is relatively low after hybridization (initial
screening). More than 50% of positive clones gave 1+ and 2+ fluorescent
intensity against Chicago 2 antigen. Ten percent gave 3+ and only 4%
gave 4+ fluorescent Intensity. The purpose of cloning and reclonlng is
to Isolate the secretor cells from the non-secretors and to obtain a
truly monoclonal cell line. The fluorescent intensity is usually higher
when all cells are producing antibody. Also, the cloning procedure
allows one to select out or remove cells that may have originally been
secretors but can no longer secret due to loss of chromosomes.
Specificity should not change unless antibodies of two different
specificities are being produced by different hybridomas. Also, the
quality of the antibody that is produced does not change. The
concentration of the antibody in the fluid will vary depending on the
number of cells that are secreting. After the secondary screening
(Fig.3) a number of clones gave 3+ and 4+ fluorescence intensity which
was higher than in the initial screening, and in the tertiary cloning and
screening (Fig.4), more clones produce 3+ and 4+ reacting antibodies.
This is because the cells represent a true clone, and non-secretors have
been removed. Also, the growth rate of the clones may increase as they
adapt to culture. IFA test results show that after the tertiary cloning
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almost 100% of the clones gave positive results. The percentage giving
4+ fluorescent intensity varied from 50-80%. In the cases where cloning
plates failed to produce antibody, hybrldomas from 24 well plates were
used to redone as soon as possible. After the selected clones were
aspirated for recloning, every plate was frozen to preserve the remaining
untested clones for future investigations.
In Table 4 it may be seen that more than 50% of the clones that
initially secreted antibody became non-secretors after the first
cloning. This instability is due in part to the loss of heavy chain and
light chain synthesis associated with chromosome loss and/or overgrowth
by non-secreting clones or variants. The rate of loss of production of
antibody in the experiment was high and the similar to that observed by
other investigators (Kwan, et al., 1980; Coding, 1980).
There are a lot of problems facing investigators in hybrldoma
technology. Observations from this study Indicate that some problems are
not yet solved. Some factors are still not clear. The exact role of
macrophages as feeder cells is still not completely understood. Every
step must be kept in mind. That is very Important. Before starting to
work each step must be understood. The screening method must be decided
before the experiment is begun and all the materials should be available
promptly. When contamination such as mold growth is observed in any well
the entire plate should be discarded. It is not advisable to save that
plate because it may be spread throughout the whole experiment. The
contaminating problem can be reduced by using aseptic techniques.
CHAPTER VI
SUMMARY
1. Mice that give a strong secondary immune response to the immunogen
are better for fusion experiments than mice that give a weak
secondary response.
2. Maximum fluorescece was obtained in IFA test with culture fluids of
hybridomas after the second recloning. Further cloning did not
result in any increase in fluorescence Intensity in the IFA test with
culture fluids, suggesting that the monoclonal cell lines of
hybridomas were obtained after two reclonings.
3. All ten monoclonal antibodies react specifically to strains of
pneumophila serogroup 6 but not to strains of serogroup 3. This
provides evidence that monoclonal antibodies can solve
cross-reactivities problems between these two serogroups.
4. Monoclonal antibodies provide a means for examining the antigenic
variation among strains of bacteria in the same serogroup.
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APPENDIX A
Myelomas Used for Hybridoma Production
Name Ig Synthesized or Cell Type
P3 X 63 Ag 8 IgGi(K)
P3-NS1/1 Ag 4-(NSl) (-)(K)










Sp25 - 4 Ag I^G(K)
45.6 TG 1.7 I G2b
g
4T061L1 K
X63 Ag 8.635 None
FO None
210.RCY 3-Ag7 K




Aatlgens Used for Characterization











































1. Stock solution (lOOX) of Hypoxanthlne and Thymidine (HT) pH 9-9.5
a. Hypoxanthlne (H) (6-hydroxypurln Sigma grade)
M.W. 136.1 Final concentration 10 M 136.1 mg
b. Thymidine (T) (Sigma grade, crystalline)
M.W. 242.2 Final concentration 3 x 10 76 mg
c. Mix and bring volume up to 100 ml with cell
culture water (double distilled water)
d. Filter through 0.2 micron filter pore
(Sybron/Nalge)
e. Freeze at - 80C.
2. Stock solution (lOOX) of (+) Amlnoptherln (A)
a. Amlnopterln (A) (Sigma grade Lot #32F 0485 anhydrous
form 4-amlno-lO-methyl folic acid;4-amlno-N^^-
pteroyglutamlc acid) pH 7.8, Final
concentration 10 ^ M 100 mg
b. Bring volume up to 200 ml with double distilled water
c. Filter and freeze at -80C
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APPENDIX D
Preparation of Growth Medium
1. Supplemented Dulbecco's Modified Eagle Medium (DMEM)
a. DMEM
b. Fetal Bovine Serum (FBS)
c. Antibiotics (Penicillin 10,000
unlt/ml, Streptomycin 10,000 unlt/ml)
d. Glutamine (200 mM)
e. 2 Mercaptoethanol (O.IM)
f. Sodium Pyruvate (100 mM)
g. Mix well In 500 ml Wheaton Screw Cap bottle
h. Filter with Nalgene Filter Unit Type LS
0.2 Micron (Sybron/Nalge)
1. Store at 4 C no longer than two weeks
2. Cloning Medium
a. DMEM
b. HT(IOOX) (Appendix C)
c. A(IOOX) (Appendix C)
d. Conditioned Medium (This medium collected from
growing myeloma cell)
e. Mix and filter













3. Preparation of Growth Medium Containing HAT
3. • Growth Medium 500 ml
b. HT (lOOX) (Appendix C) 5 ml
c. A (lOOX) (Appendix C) 5 ml
d. Mix and filter
e. Store at 4 C
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APPENDIX E
Preparation of Polyethylene Glycol
1. Use 8U218 J.T. Baker TM Grade (MW-1000). Lot #049385,
2. Melt and sterilize by autoclaving for 30 minutes.
3. Mix cool but liquified PEG, 3 ml
DMEM 5.95 ml
IM HEPES (N-2-Hydroxyethyl plperazlne-N-2-ethan-
sulfonlc acid.) 1.05 ml.
4. Adjust pH to 8.2
5. Store frozen.




Immunofluorescence Buffers, Fixative Agent and Mounting Fluids
1. Phosphate Buffer Saline (PBS), pH 7.6, O.OlM:a.Concentrated Stock Solution (pH 7.6)
NaH2P04 H2O
Na2HP04 (anhydrous, reagent grade)
NaCl (reagent grade)




4 literb.Working Solution (pH7.6, O.OlM)
Concentrated stock solution 100 ml
Distilled water to make final volume 1 liter
c. 1% formalin PBS
PBS working solution 99 ml
Formalin (37%-38%) 1 ml
d. 0.5% formalin PBS
PBS working solution 99.5 ml
Formalin (37%-38%) 0.5 ml
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APPENDIX F (continued)
2. Glycerol mounting fluid: Buffered glycerine (pH 8.3)
(FA mounting medium)
0.2M Na2HP04 10 ml
Glycerine (reagent grade) 90 ml
Combine and mix by stirring (do not shake)
3. Kirpatrick's fixative agent
Absolute ethyl alcohol 60 ml
Chloroform 30 ml





95% relative humidity (distilled water supply containing 10 mg/1
cycloheximlde)
37 C temperature
63
